London
Roots Analysis
Despite mammalian
cell cultures being the preferred manufacturing approach for biologics, recent advances
in microbial fermentation have enabled the development of versatile
biomanufacturing systems, which are both robust and cost friendly. Presently, a
number of service provider companies claim to offer end-to-end solutions,
ranging from product development to commercial production, for microbial biologics.
Given the obvious advantages of outsourcing, drug developers are likely to
continue relying on contract service providers for various aspects of their
respective microbial biologic development programs.
To
order this 320+ page report, which features 150+ figures and 150+ tables,
please visit this - https://www.rootsanalysis.com/reports/microbial-contract-biomanufacturing-market.html
Key Market Insights
Over 115 CMOs claim
to offer manufacturing services for microbial biologics
The microbial contract
biomanufacturing market is highly fragmented, featuring a mix of small,
mid-sized, large and very large players. It is worth mentioning that more than
50% of CMOs mentioned in the report, have the necessary capabilities to
manufacture biologics across all scales of operation (preclinical, clinical
and commercial).
Recently, a number of
microbial biologics manufacturers are shifting to yeast-based production systems.
It is also worth highlighting that close to 30% of CMOs, identified in this
research, claim to have the required capabilities to manufacture biologics using
both bacterial and yeast-based systems.
There are more than
150 manufacturing facilities, with microbial fermentation capabilities, worldwide;
of these, 43% are in Europe, followed by North America (31%). On the other
hand, prominent regions in the Asia Pacific and Middle East, where microbial biologics
are manufactured, include (in decreasing order of number of resident manufacturing
facilities) China, India, Japan, Australia and Israel.
Several partnerships
were established in this domain, during the period 2016-2020
Majority of the deals
recorded in the report, were established in 2019. Further, a large number (~25%)
of the partnerships were observed to be focused on the production of microbial
biologics; this is followed by process development and manufacturing agreements
(20%).
Further, multiple
expansion initiatives were undertaken by CMOs, since 2016
More than 30% of expansion
projects over the last few years were focused on the establishment of new
facilities, followed by those involving the expansion of existing manufacturing
facilities (28%). Further, 50% of the expansion initiatives mentioned in the
report, were in undertaken by stakeholder companies in Europe, followed North
America (39%).
Big pharma players
have also been active in this upcoming field
Around 60% of the initiatives
undertaken by big pharma were reported in the period 2016-2020. Of these, 57% involved
the establishment of strategic partnerships with other industry stakeholders. It is worth highlighting that, in terms of type of
biologic, close to
North America and
Europe are anticipated to capture over 80% share (in terms of service
revenues) of the market, by 2030
At present, more than
60% of the total revenues are generated from commercialized microbial
biologics, and this trend is unlikely to change significantly in short to
mid-term. Further, it is worth mentioning that the contract biomanufacturing market
for microbial biologics in the Middle East and North Africa is anticipated to
grow at a relatively faster rate (10.3%), followed by Asia Pacific (9%).
To request a sample copy / brochure of this report, please visit
this
Key
Questions Answered
§
§
§
§
§
§
§
§
The USD 9.3 billion (by 2030) financial opportunity
within the microbial contract biomanufacturing market has been analyzed across
the following segments:
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
The report features
inputs from eminent industry stakeholders, according to whom, currently, over
50% operations related to both API and FDF manufacturing of microbial biologics
are outsourced to third party service providers. The report includes detailed
transcripts of discussions held with the following experts:
§ Gaurav Kaushik (Chief
Executive Officer and Managing Director, Meteoric
Biopharmaceuticals)
§ Debbie Pinkston (Vice
President, Sales and Business Development, List Biological Laboratories)
§ Andrea Conforto
(Sales and Marketing, Bioservices Director, Olon)
§ Max Rossetto (General
Manager, Business Development, Luina
Bio)
§ Rob van Dijk
(Business Development Manager, WACKER
Biotech)
The research covers
profiles of key players (listed below); each profile features an
overview of the company, information related to its microbial manufacturing
focused service portfolio, production facilities and capabilities, and an
informed future outlook.
§
§
§
§
§
§
§
§
§
§
For additional
details, please visit
https://www.rootsanalysis.com/reports/microbial-contract-biomanufacturing-market.html or
email sales@rootsanalysis.com
You may also be
interested in the following titles:
1.
2.
3.
Contact:
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091